Sponsor:
NYU Langone Health
Code:
NCT05641753
Conditions
Type 1 Diabetes
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
Evolocumab Cartridge
Atorvastatin Calcium Tablets
Ezetimibe Tablets
18F-FDG
Angiocatheter 20IV
Brief summary:
Conditions
Type 1 Diabetes
Study ID
NCT05641753
Start date
Dec 6, 2022
Status verified date
Dec, 2025
Completion date
Jul 31, 2027
Anticipated
Primary completion date
Jul 1, 2027
Anticipated
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Enrollment
125 participants
Anticipated
Intervention Model
Single group
Primary purpose
Other
Arms
experimental: 4-Week LDL-Cholesterol (LDL-C)-Reduction Treatment
Interventions
Evolocumab Cartridge
Atorvastatin Calcium Tablets
Ezetimibe Tablets
18F-FDG
Angiocatheter 20IV
J-Wire
GlycoCheck Glycocalyx Measurement Software
Primary outcome measure
Central contacts
Locations
New York VA Hospital
Recruiting
New York, New York, United States, 10010
NYC Health + Hospitals/Bellevue
Recruiting
New York, New York, United States, 10016
NYU Langone Health
Recruiting
New York, New York, United States, 10016
Mount Sinai School of Medicine
Recruiting
New York, New York, United States, 10029
Principal Investigator:
Zahi Fayad
Sponsor
NYU Langone Health
Last update posted
Dec 29, 2025
Last verified
Dec, 2025
Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by NYU Langone Health on 2025-12-29.